Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End

Iovance Biotherapeutics (IOVA) was in the spotlight on Friday after the biotech firm reported promising results from a Phase 2 trial of its experimental cell therapy Lifileucel,…

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (stocktwits.com)